Molex company Phillips-Medisize has launched a new disposable pen injector to reduce pharma costs and risks as well as market barriers.
Designed to support high-volume manufacturing, the new pen injector is expected to help pharmaceutical companies in efficient and cost-effective market entry.
The pen injector platform is part of the company’s Aria Smart Autoinjector, which was launched in May 2021 to meet the requirements of the digital drug-delivery device market.
Having a compact form factor feature, the pen injector has a flexible design with customisable dosing and push-button colours to meet different dosing and drug requirements for several therapies.
These therapies include diabetes, fertility, growth hormones, obesity and osteoporosis.
The company is offering sample devices for technical assessment and human factors studies.
With this pen injector, drug-delivery companies will be able to respond to the rapidly rising disposable pen injector market.
Molex Medical and Pharmaceutical Solutions president and senior vice-president Paul Chaffin said: “A Pen Injector is an important addition to Phillips-Medisize’s expanding product and platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale.
“This ‘ready to go’ solution offers all of the advantages expected from ‘state of the art’ pen designs, while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”
Phillips-Medisize, which is a provider of integrated, end-to-end solutions, is engaged in the production of around 400 million medical devices a year for its customers.